The Alterations of Microvasculature, Tyrosine Phosphorylation, and Lipid Peroxidation in Kidney of Rats Treated with Valproic Acid

DOI :
Tweet about this on TwitterShare on FacebookEmail this to someoneShare on Google+

Chanwit Maneenin; Natthapol Lapyuneyong; Saranya Tongpan; Supataechasit Yannasithinon; Jaturon Burawat; Naowarat Maneenin; Wannisa Sukhorum; Supatcharee Arun & Sitthichai Iamsaard

Summary

Valproic acid (VPA), an antiepileptic drug, has been demonstrated to damage histology and to change tyrosine phosphorylation patterns with increased oxidative stress in perirenal tissues. This study aimed to investigate the effect of VPA on microstructure, tyrosine phosphorylation, and lipid peroxidation of rat kidney. Adult male rats were divided into control and VPA-treated groups intraperitoneally injected with normal saline and VPA 500 mg/kgBW for 10 consecutive days, respectively (n = 7 each). The blood serum was examined for biochemical levels. The kidney tissues were routinely processed for histological observation. Total proteins from kidney were extracted to assay the malondialdehyde (MDA) levels and phosphorylation expression. The results showed that VPA significantly decreased blood glucose levels while tend to increase urea nitrogen and creatinine. MDA levels in VPA group were significantly higher that of control. Renal cortex of VPA-treated animals revealed vasodilatations. Although the ratio of a renal phosphorylated 72 kDa protein/ beta actin expression seemed to be not different in both groups, VPA significantly decreased the intensity of beta actin. In conclusion, VPA dilates renal microvasculature with increasing of MDA but suppresses the actin expression.

KEY WORDS: Valproic acid; Vasodilatation; Tyrosine phosphorylation; Kidney; Rats.

How to cite this article

MANEENIN, C.; LAPYUNEYONG, N.; TONGPAN, S.; YANNASITHINON, S.; BURAWAT, J.; MANEENIN, N.; SUKHORUM, W.; ARUN, S. & IAMSAARD, S. The alterations of microvasculature, tyrosine phosphorylation, and lipid peroxidation in kidney of rats treated with valproic acid. Int. J. Morphol., 37(1):65-70, 2019.